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Here, we developed a model system to evaluate the metabolic effects of oncogene(s) on the host microenvironment. 
A matched set of “normal” and oncogenically transformed epithelial cell lines were co-cultured with human fibroblasts, to 
determine the “bystander” effects of oncogenes on stromal cells. rOS production and glucose uptake were measured by 
FACS analysis. In addition, expression of a panel of metabolic protein biomarkers (Caveolin-1, MCt1, and MCt4) was ana-
lyzed in parallel. Interestingly, oncogene activation in cancer cells was sufficient to induce the metabolic reprogramming of 
cancer-associated fibroblasts toward glycolysis, via oxidative stress. evidence for “metabolic symbiosis” between oxidative 
cancer cells and glycolytic fibroblasts was provided by MCt1/4 immunostaining. As such, oncogenes drive the establish-
ment of a stromal-epithelial “lactate-shuttle”, to fuel the anabolic growth of cancer cells. Similar results were obtained with 
two divergent oncogenes (rAS and NFkB), indicating that rOS production and inflammation metabolically converge on 
the tumor stroma, driving glycolysis and upregulation of MCt4. these findings make stromal MCt4 an attractive target 
for new drug discovery, as MCt4 is a shared endpoint for the metabolic effects of many oncogenic stimuli. thus, diverse 
oncogenes stimulate a common metabolic response in the tumor stroma. Conversely, we also show that fibroblasts pro-
tect cancer cells against oncogenic stress and senescence by reducing rOS production in tumor cells. ras-transformed 
cells were also able to metabolically reprogram normal adjacent epithelia, indicating that cancer cells can use either fibro-
blasts or epithelial cells as “partners” for metabolic symbiosis. the antioxidant N-acetyl-cysteine (NAC) selectively halted 
mitochondrial biogenesis in ras-transformed cells, but not in normal epithelia. NAC also blocked stromal induction of 
MCt4, indicating that NAC effectively functions as an “MCt4 inhibitor”. taken together, our data provide new strategies for 
achieving more effective anticancer therapy. We conclude that oncogenes enable cancer cells to behave as selfish “meta-
bolic parasites”, like foreign organisms (bacteria, fungi, viruses). thus, we should consider treating cancer like an infectious 
disease, with new classes of metabolically targeted “antibiotics” to selectively starve cancer cells. Our results provide new 
support for the “seed and soil” hypothesis, which was first proposed in 1889 by the english surgeon, Stephen Paget.
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Introduction
Previous studies have shown that mutational activation 
and/or overexpression of diverse oncogenes is indeed sufficient to 
confer cell transformation and to drive tumor growth and metas-
tasis in whole-animal models.1,2 This has led to the over-simplified 
notion that cancer is a cell-autonomous disease. However, this 
view is inherently incomplete, as it does not explain the critical role 
of the tumor microenvironment or the host organism in tumor 
initiation, progression, and metastasis.3-7 As such, a more global 
or metabolic view of cancer will be necessary for us to begin to 
design and implement new more effective anticancer therapies.8-11
Also, little is known regarding the process of tumor cell engraft-
ment. We believe that understanding the metabolic requirements 
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for tumor cell engraftment should allow us to develop new strate-
gies for cancer prevention and therapy. Tumor cell engraftment 
most likely requires that the cancer cells gain the ability to meta-
bolically reprogram their microenvironment, essentially a “nest-
ing” type of cell behavior. In support of this notion, many human 
epithelial tumor types consist of “cancer cell nests”, surrounded 
by cancer-associated fibroblasts, which were originally thought to 
play mainly a structural role.
However, more recent studies indicate that epithelial cancer 
cells also derive many of their nutrients directly from cancer-asso-
ciated fibroblasts and other stromal cells, such as adipocytes.12-54 
This would be especially critical during the early phases of tumor 
initiation and the later stages of metastasis, when a neo-angio-
genic blood supply is clearly lacking. We have termed this type 
of symbiotic relationship between cancer cells and stromal cells 
“two-compartment tumor metabolism.”31,33,40,42-45 In this scenario, 
glycolytic fibroblasts directly provide mitochondrial fuels (such as 
L-lactate and ketone bodies) for oxidative cancer cells to burn 
via the TCA cycle and OXPHOS. This energy transfer scheme 
also requires the establishment of a stromal-epithelial “lactate 
shuttle”, for the efficient transfer of these high-energy nutrients 
from fibroblasts to cancer cells. To accomplish this metabolic cou-
pling, fibroblasts export L-lactate and ketone bodies via MCT4 
transporters.55,56 In turn, epithelial cancer cells import and recycle 
these fuels via the MCT1 transporter to produce ATP efficiently.
So, how do we integrate the “oncogene theory” of cancer with 
this new form of cancer metabolism or “metabolic symbiosis”? 
One simple idea is that oncogenes give cancer cells the ability 
to manipulate and/or sculpt their microenvironment for their 
own personal benefit at a significant cost to the host organism.31 
This would also mechanistically explain tumor cell engraftment. 
Thus, oncogenes may give predatory cancer cells the ability to 
function as “metabolic parasites”. This would mean that onco-
genes in epithelial cancer cells must also have long-distance or 
bystander effects on the tumor microenvironment in order for 
cancer cells to make a proper nest.
Here, we have begun to test this new hypothesis using a 
matched set of 3 well-defined epithelial cell lines.57 The parental 
cell line (HaCaT cells) is immortalized, but not transformed, and 
does not form tumors in nude mice, so it is incapable of can-
cer cell engraftment.58 The two other HaCaT cells lines we used 
harbor activated oncogenes (H-Ras [G12V] or NFkB [p65]), are 
transformed, and form tumors in nude mice, so they efficiently 
undergo cancer cell engraftment. Interestingly, we show that 
only HaCaT cells that harbor activated oncogenes gain the abil-
ity to glycolytically reprogram the tumor microenvironment, via 
the induction of oxidative stress in cancer-associated fibroblasts. 
Thus, it appears that oncogenes also act at a distance, via ROS 
production and inflammation, to induce metabolic symbiosis 
between cancer cells and the tumor stroma. As a consequence, 
diverse oncogenes (Ras and NFkB) act via a common convergent 
mechanism (oxidative stress) to upregulate MCT4 in the tumor 
stroma. As MCT4 controls the “fuel supply” for cancer cells, this 
makes MCT4 an extremely attractive druggable target for new 
therapeutic interventions aimed at “starving” oncogenically acti-
vated tumor cells. As such, diverse oncogenes stimulate a common 
metabolic response to “injury” in the tumor microenvironment. 
Figure  1. the HaCat cell system: Immortalized and transformed with 
oncogenes. HaCat cells are immortalized epidermal keratinocytes, but 
they are not transformed, and they do not form tumors in immunodefi-
cient mice. However, overexpression of activated H-ras (G12V) or NFkB 
(p65 subunit) drives cell transformation, and confers the capacity for 
tumor cell engraftment, leading to tumor formation in nude mice. thus, 
phenotypic comparisons of these 3 matched cell lines should allow one 
to better understand the metabolic requirements for successful tumor 
cell engraftment within the naïve host microenvironment.
Figure 2. HaCat-fibroblast co-cultures: transformed HaCat cells show a 
modest increase in rOS production, without any significant increases in 
glucose uptake. (A) rOS-production. (B) Glucose uptake. HaCat epithelial 
cells (control, H-ras [G12V], or NFkB [p65]) were co-cultured for 4 days with 
htert-immortalized fibroblasts (rFP[+]). then, rOS production (a measure 
of oxidative stress) and glucose uptake (a measure of glycolytic activity) 
in HaCat cells were quantitatively determined by FACS sorting. Note that 
only HaCat-ras cells show a significant increase in rOS production (1.5-
fold; P = 0.03), without any detectable increases in glucose uptake.
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This idea is consistent with the hypothesis that cancer behaves as 
a wound that does not heal.
N-acetyl-cysteine (NAC) is among the smallest FDA-approved 
drug molecules currently in use, and it has both antioxidant and 
anti-inflammatory properties. Surprisingly, however, it is not used 
clinically for the treatment of human cancers. As we show here 
that NAC inhibits the induction of stromal MCT4 by preventing 
oxidative stress, this may also explain why NAC so effectively pre-
vents tumor initiation, progression, and metastasis, in numerous 
pre-clinical animal models.59-70 As such, new clinical trials with 
NAC should be considered, to alleviate oxidative stress and inflam-
mation in the tumor microenvironment. In addition, since NAC 
effectively functions as an “MCT4 inhibitor”, the development of 
more targeted and selective MCT4 inhibitors may be warranted.
Results
HaCaT cells: An experimental model for understanding the 
requirements of tumor cell engraftment
HaCaT cells are considered to be a relatively “normal”, non-
transformed, spontaneously immortalized human epithelial kerati-
nocyte cell line.58 In accordance with this idea, they fail to form 
tumors in immunodeficient mouse animal models.58 Thus, they 
are an ideal cell line to study the factors that are required for suc-
cessful tumor cell engraftment. Indeed, several laboratories have 
now shown that the recombinant expression of activated oncogenes 
in HaCaT cells is sufficient to confer effective cell transformation 
and tumor formation in nude mice. In this regard, expression of 
either activated H-Ras (G12V) or the p65 subunit of NFkB in 
HaCaT cells greatly facilitates successful tumor cell engraftment.57
Thus, this isogenic matched series of HaCaT cell lines (con-
trol, H-Ras [G12V], and NFkB [p65]) provides a unique, well-
characterized model system to begin to dissect the possible 
metabolic requirements for tumor formation and efficient epithe-
lial tumor cell engraftment (Fig. 1).
For this purpose, we co-cultured HaCaT cells with hTERT-
immortalized fibroblasts, to mimic and monitor their reciprocal 
interactions with the host tumor microenvironment.
Ras activation and inflammation in epithelial cancer cells 
metabolically alters the tumor microenvironment, driving stro-
mal oxidative stress and glycolysis
To model and dissect the metabolic basis of tumor-stromal 
interactions, epithelial HaCaT cells (control, H-Ras [G12V], and 
Figure  3. HaCat-fibroblast co-cultures: Cancer-associated fibroblasts 
show dramatic increases in both rOS production and glucose uptake. 
(A) rOS-production. (B) Glucose uptake. HaCat epithelial cells (control, 
H-ras [G12V], or NFkB [p65]) were co-cultured for 4 days with htert-
immortalized fibroblasts (rFP[+]). then, rOS production (a measure of 
oxidative stress) and glucose uptake (a measure of glycolytic activity) in 
htert-fibroblasts were quantitatively determined by FACS sorting. Note 
that htert-fibroblasts co-cultured with HaCat-ras cells show a significant 
increase in both rOS production (2.5-fold; P = 0.008) and glucose uptake 
(2.2-fold; P = 0.03). Similarly, htert-fibroblasts co-cultured with HaCat-p65 
cells show a significant increase in rOS production (1.9-fold; P = 0.01) and 
glucose uptake (1.7-fold; P = 0.02). thus, oncogene-transformed epithelial 
cancer cells metabolically reprogram adjacent normal fibroblasts.
Figure  4. Cancer-associated fibroblasts Show the largest increases in 
rOS production and glucose uptake, as directly compared with adjacent 
epithelial cancer cells. (A) rOS-production. (B) Glucose uptake. Data 
originally presented in Figures 2 and 3 is presented again in Figure 4, in 
another format. In this case, the absolute magnitude of rOS production 
and glucose uptake in epithelial cancer cells and fibroblasts is directly 
compared, side-by-side, on the same graphs. this allows one to better 
appreciate that although the epithelial cancer cells harbor the activated 
oncogenes, their largest effects on cellular metabolism actually occur in 
neighboring normal fibroblasts. thus, the “bystander” effect of onco-
genes on the tumor microenvironment is one of the most significant 
metabolic effects, in terms of metabolic reprogramming.
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NFkB [p65]) were co-cultured with immortalized fibroblasts and 
then subjected to FACS analysis with a series of fluorescent meta-
bolic probes. These small reporter molecules allowed us to quan-
titatively monitor ROS production (a measure of oxidative stress) 
and glucose uptake (a measure of glycolysis or glycolytic power) in 
a compartment-specific fashion. Thus, we compared ROS produc-
tion and glucose uptake in epithelial cancer cells and adjacent nor-
mal fibroblasts to determine how epithelial oncogene activation 
metabolically reprograms the tumor stromal microenvironment.
Figure 2A and B show the status of these metabolic param-
eters in HaCaT cells co-cultured with fibroblasts. Interestingly, 
Ras activation leads to a 1.5-fold increase in ROS production, as 
expected based on the literature. However, NFkB activation did 
not increase ROS production significantly. Moreover, oncogene-
activation (Ras or NFkB) did not result in increased glucose 
uptake. Thus, the metabolic effects of oncogene activation in epi-
thelial cancer cells appeared to be relatively minimal.
Next, we examined ROS production and glucose uptake in the 
population of hTERT fibroblasts co-cultured with HaCaT cells 
(Fig. 3A and B). Large metabolic changes were observed in both 
Figure 5. ras oncogene activation and inflammation drive a loss of Cav-1 
expression in adjacent cancer-associated fibroblasts. (A) HaCat epithe-
lial cells (control, H-ras [G12V], or NFkB [p65]) were co-cultured for 4 days 
with htert-immortalized fibroblasts (GFP+). then, the cells were fixed 
and immunostained with specific antibody probes. Note that a loss of 
stromal Cav-1 occurs only in fibroblasts co-cultured with HaCat-ras and 
HaCat-p65 cells. HaCat control cells did not induce a loss of Cav-1 in stro-
mal fibroblasts. DAPI (blue nuclear staining) is also shown for reference. 
(B) Image quantitation regarding the oncogene-induced loss of stromal 
Cav-1 is presented; note that there is a significant 2–3-fold reduction in 
Cav-1 expression.
Figure 6. ras oncogene activation and inflammation drive the upregu-
lation of MCt4 expression in adjacent cancer-associated fibroblasts. (A) 
HaCat epithelial cells (control, H-ras [G12V], or NFkB [p65]) were co-cul-
tured for 4 days with htert-immortalized fibroblasts (GFP+). then, the 
cells were fixed and immunostained with specific antibody probes. Note 
that MCt4 expression is increased most significantly in fibroblasts co-
cultured with HaCat-ras and HaCat-p65 cells. In contrast, HaCat control 
cells only induced a mild or modest increase in stromal MCt4 expres-
sion. DAPI (blue nuclear staining) is also shown for reference. (B) Image 
quantitation regarding the oncogene-induced upregulation of stromal 
MCt4 at day 4 is presented; note that there is a significant 3-fold upregu-
lation of MCt4 expression. P values vs. fibroblasts alone (P < 0.0007) and 
vs. HaCat-CtrL co-cultures (P < 0.004) are both shown. (C) Image quan-
titation regarding the oncogene-induced upregulation of stromal MCt4 
at day 5 is presented; note that there is a significant 4-fold upregula-
tion of MCt4 expression. P values vs. fibroblasts alone (P < 0.01) and 
vs. HaCat-CtrL co-cultures (P < 0.001) are both shown.
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ROS production and glucose uptake. More specifically, hTERT-
fibroblasts co-cultured with HaCaT-Ras cells showed a significant 
increase in both ROS production (2.5-fold; P = 0.008) and glu-
cose uptake (2.2-fold; P = 0.03). Similarly, hTERT-fibroblasts co-
cultured with HaCaT-p65 cells showed a significant increase in 
ROS production (1.9-fold; P = 0.01) and glucose uptake (1.7-fold; 
P = 0.02). Thus, oncogene-transformed epithelial cancer cells 
metabolically reprogram adjacent normal fibroblasts.
Cancer-associated fibroblasts produce more ROS and are 
more glycolytic, as directly compared with epithelial cancer cells
Figure 4 shows the absolute magnitude of ROS production 
and glucose uptake in epithelial cancer cells and fibroblasts. This 
direct, side-by-side comparison allows one to appreciate that 
although the epithelial cancer cells harbor the activated onco-
genes, their largest effects on cellular metabolism are actually 
occurring in neighboring normal fibroblasts.
Thus, the “bystander” effect of oncogenes on the tumor micro-
environment appears to be one of the most significant metabolic 
effects, in terms of metabolic reprogramming.
Ras oncogene activation and inflammation drive a loss of stro-
mal Cav-1 expression in adjacent cancer-associated fibroblasts
Loss of stromal caveolin-1 (Cav-1) is a biomarker of poor clini-
cal outcome in several distinct types of human epithelial cancers, 
including breast, prostate, and gastric carcinomas, as well as in 
metastatic melanoma.71-82 In human breast cancers, reductions 
in stromal Cav-1 are clinically associated with early tumor recur-
rence, lymph-node metastasis, tamoxifen-resistance, and prema-
ture death. Mechanistically, loss of Cav-1 occurs via autophagic/
lysosomal degradation due to oxidative stress in cancer-associated 
fibroblasts.30 Thus, loss of stromal Cav-1 is a functional biosen-
sor of oxidative stress, autophagy, and glycolysis in the tumor 
microenvironment.22,34
As a consequence, we next examined the ability of HaCaT 
cells to downregulate Cav-1 expression in normal adjacent fibro-
blasts, during co-culture. For this purpose, HaCaT epithelial 
cells (control, H-Ras [G12V], or NFkB [p65]) were co-cul-
tured with hTERT-immortalized fibroblasts (GFP[+]). Then, 
the cells were fixed and immunostained with specific antibody 
probes. Figure 5A shows that loss of stromal Cav-1 occurs only 
in fibroblasts co-cultured with HaCaT-Ras and HaCaT-p65 cells. 
However, HaCaT control cells did not induce a loss of Cav-1 in 
stromal fibroblasts. Image quantitation regarding the oncogene-
induced loss of stromal Cav-1 is presented in Figure 5B. Note 
that there is a significant 2–3-fold reduction in Cav-1 expression.
Thus, a loss of stromal Cav-1 is essentially a “mirror” or 
“reporter” of oncogenic transformation in adjacent epithelial can-
cer cells during the transition to malignancy.
Ras oncogene activation and inflammation drive the upreg-
ulation of MCT4 expression in adjacent cancer-associated 
fibroblasts, via oxidative stress
Like Cav-1, MCT4 is another biomarker of oxidative stress 
in cancer-associated fibroblasts.55,56 In head and neck cancers, 
Figure 7. Oxidative stress mediates the upregulation of MCt4 in cancer-
associated fibroblasts: rescue with NAC, a powerful antioxidant. HaCat 
epithelial cells (control, H-ras [G12V], or NFkB [p65]) were co-cultured for 
5 days with htert-immortalized fibroblasts (GFP+). then, the cells were 
fixed and immunostained with specific antibody probes. Note that MCt4 
expression is increased most significantly in fibroblasts co-cultured with 
HaCat-ras cells and HaCat-p65 cells, and that this can be reversed or 
prevented by the addition of the powerful antioxidant, N-acetyl cyste-
ine (NAC) [10 mM], to the culture media. (A) HaCat control co-cultures; 
(B) HaCat-ras co-cultures; (C) HaCat-p65 co-cultures. DAPI (blue nuclear 
staining) is also shown for reference.
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MCT4 is a highly specific marker of cancer-associated fibro-
blasts, as compared with normal fibroblasts.83 In addition, stro-
mal MCT4 expression in triple-negative breast cancers is a single 
independent powerful predictor of poor clinical outcome.84 In 
this context, a loss of stromal Cav-1 is strictly correlated with 
stromal MCT4 upregulation and lethality in triple-negative 
breast cancer patients.84 Physiologically, MCT4 allows the effi-
cient export of L-lactate and ketone bodies from glycolytic cells. 
Mechanistically, MCT4 is a HIF1-α target gene that is upregu-
lated under conditions of hypoxia and/or oxidative stress (a.k.a., 
pseudo-hypoxia). Hence, MCT4 is a functional biomarker of 
oxidative stress, hypoxia, and glycolysis, as well as mitochondrial 
dysfunction.
As such, we next examined the ability of HaCaT cells to upreg-
ulate MCT4 expression in normal adjacent fibroblasts during co-
culture. HaCaT epithelial cells (control, H-Ras [G12V] or NFkB 
[p65]) were co-cultured with hTERT-immortalized fibroblasts 
(GFP+). Then, the cells were fixed and immunostained with 
specific antibody probes. Figure 6A shows that MCT4 expres-
sion is increased most significantly in fibroblasts co-cultured with 
HaCaT-Ras and HaCaT-p65 cells. In contrast, HaCaT control 
cells only induce a mild or modest increase in stromal MCT4 
expression, close to the “border” or epithelial-stromal interface. 
Image quantitation regarding the oncogene-induced upregula-
tion of stromal MCT4 is presented in Figure 6B and C. Note 
that stromal MCT4 expression is increased by up to > 4-fold dur-
ing fibroblast co-culture with HaCaT-Ras and HaCaT-p65 cells.
To directly validate the idea that increased MCT4 expression 
represents oxidative stress in cancer-associated fibroblasts, we 
explored the functional effects of N-acetyl cysteine (NAC) [10 
mM], a powerful antioxidant. Indeed, Figure 7 shows that NAC 
treatment reversed or prevented the induction of MCT4 in the 
stromal microenvironment in Ras and NFkB co-cultures only, 
directly implicating oxidative stress. Quantitation of these find-
ings is presented in Figure 8A and B. Note that NAC treatment 
normalizes MCT4 expression in HaCaT-Ras and HaCaT-p65 
co-cultures. Thus, NAC effectively functions as an “MCT4 
inhibitor”.
Co-culture with fibroblasts upregulates the expression of 
MCT1 in Ras-transformed and NFkB-expressing epithelial 
cancer cells: Establishment of metabolic symbiosis
We have previously provided evidence that a “lactate shuttle” 
exists in human tumors.45,55,56,83 In this scenario, cancer-associ-
ated fibroblasts express MCT4 and export mitochondrial fuels 
(such as L-lactate and ketone bodies) into the tumor microen-
vironment. Conversely, epithelial cancer cells express MCT1, 
which allows them to efficiently import these mitochondrial fuels 
to “burn” as an energy source for oxidative mitochondrial metab-
olism. This metabolic symbiosis mechanism could represent how 
tumor cells achieve efficient engraftment by metabolically co-
operating with and rewiring their host microenvironment. To 
further test this hypothesis, we next examined the expression of 
MCT1 in HaCaT cells, either cultured alone or in the presence 
of stromal fibroblasts.
More specifically, HaCaT epithelial cells (control, 
H-Ras [G12V], or NFkB [p65]) were co-cultured with 
hTERT-immortalized fibroblasts (GFP[+]). Alternatively, 
HaCaT cells were cultured alone (without fibroblasts) for the 
same amount of time. Then, the cells were fixed and immunos-
tained with specific antibody probes.
Figure 9 shows that MCT1 expression and plasma membrane 
localization is increased most significantly in HaCaT-Ras cells 
and HaCaT-p65 cells co-cultured with fibroblasts, relative to the 
same HaCaT cells cultured alone. Thus, induction of MCT1 
in epithelial cancer cells is a functional biomarker of “meta-
bolic symbiosis”, which occurs during co-culture with stromal 
fibroblasts.
Interestingly, we have previously shown that MCT1 is a bio-
marker of increased mitochondrial mass and activity, as well as 
high proliferation rates in vivo.83 For example, MCT1 expres-
sion is tightly correlated with Ki-67 immunostaining in head and 
neck cancers and in normal mucosal tissues, especially within 
the basal stem cell compartment.83 Thus, MCT1 may also be a 
marker of increased stem cell activity.
Figure  8. NAC quantitatively reduces oncogene-induced expression 
of MCt4 in cancer associated fibroblasts. (A) HaCat-ras co-cultures; (B) 
HaCat-p65 co-cultures. MCt4 expression, illustrated in Figure 7, was sub-
jected to image quantitation, as detailed under “Materials and Methods”. 
Note that HaCat-ras and HaCat-p65 cells significantly induce MCt4 
expression in adjacent stromal fibroblasts, during co-culture. However, 
treatment with NAC [10 mM] reduced stromal MCt4 expression levels by 
nearly 3-fold, approaching baseline levels. thus, NAC effectively func-
tions as an “MCt4 inhibitor”.
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Homotypic cultures of epithelial cancer cells show that 
Ras transformation increases ROS production and MCT4 
expression
For comparison purposes, we also examined some of the met-
abolic properties of HaCaT cells cultured alone under homotypic 
culture conditions. For this purpose, HaCaT epithelial cells 
(control, H-Ras [G12V], or NFkB [p65]) were cultured alone 
and then subjected to either FACS analysis to determine ROS 
production, or immunostaining with antibodies directed against 
MCT4, a marker of oxidative stress.
Interestingly, Figure 10 shows that Ras-activation in 
HaCaT cells significantly increases ROS production (Fig. 10A; 
1.5-fold; P = 0.02) and MCT4 expression at the plasma mem-
brane (Fig. 10B). Thus, HaCaT-Ras cells cultured alone also 
show an increase in oxidative stress. In contrast, HaCaT-p65 cells 
did not show significant evidence of oxidative stress when cul-
tured alone. Thus, they may induce oxidative stress in fibroblasts 
via cytokine production.
Importantly, co-culture of normal and epithelial cancer cells 
with fibroblasts reduced ROS-production in all cases, indicat-
ing that fibroblasts may help induce an antioxidant response in 
adjacent epithelial cells and protect epithelial cells from oxida-
tive stress (Fig. 10C). These findings are consistent with recent 
studies showing that bone marrow-derived stromal cells provide 
cysteine (cys), which is transferred to cancer cells (in chronic 
lymphocytic leukemia [CLL]) and is then converted to glutathi-
one (gamma-glut-cys-gly), fueling an antioxidant response.85
Oncogene activation can drive the upregulation of mito-
chondrial activity in epithelial cancer cells
We also examined the functional effects of oncogenic trans-
formation on the status of mitochondria in epithelial cancer 
cells. Briefly, HaCaT epithelial cells (control, H-Ras [G12V], or 
NFkB [p65]) were cultured alone and then subjected to FACS 
analysis to determine mitochondrial activity, via MitoTracker 
staining.
Figure 11 shows that HaCaT-Ras cells (1.5-fold; P = 0.009) 
and HaCaT-p65 cells (1.6-fold; P = 0.006) both show a signifi-
cant increase in MitoTracker activity staining. Thus, oncogenic 
tranformation can also promote increases in mitochondrial 
mass and/or activity in epithelial cancer cells, so that they are 
“primed” to undergo metabolic symbiosis with a glycolytic stro-
mal microenvironment.
Antioxidants inhibit mitochondrial biogenesis in Ras-
transformed cancer cells
We also followed mitochondrial mass in HaCaT using a spe-
cific mitochondrial marker, namely TOMM20, which also serves 
as a marker of mitochondrial biogenesis. In these studies, HaCaT 
epithelial cells (control, H-Ras [G12V], or NFkB [p65]) were 
cultured alone (in the absence or presence of NAC [10 mM]) and 
then subjected to immunostaining with TOMM20.
Figure  9. Co-culture with fibroblasts upregulates the expression of 
MCt1 in ras-transformed and NFkB-expressing epithelial cells. HaCat 
epithelial cells (control, H-ras [G12V], or NFkB [p65]) were co-cultured for 
5 days with htert-immortalized fibroblasts (GFP+). Alternatively, HaCat 
cells were cultured alone (without fibroblasts) for the same amount of 
time. then, the cells were fixed and immunostained with specific anti-
body probes. Note that MCt1 expression and plasma membrane local-
ization is increased most significantly in HaCat-ras cells and HaCat-p65 
cells co-cultured with fibroblasts, relative to the same HaCat cells cul-
tured alone. Insets at higher magnification are shown to highlight the 
plasma membrane staining of MCt1. DAPI (blue nuclear staining) is also 
shown for reference.
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Figure 12 illustrates that HaCaT-Ras cells show the most 
significant increases in mitochondrial mass (consistent with the 
MitoTracker data), and that this is strictly dependent on oxidative 
stress. Note that NAC treatment almost completely eliminated 
mitochondrial staining in HaCaT-Ras, but had little or no effect 
on mitochondrial mass in HaCaT-p65 cells and control HaCaT 
cells. As such, it appears that NAC selectively halts mitochondrial 
biogenesis in Ras-transformed cells, possibly explaining how 
antioxidants could be used to “starve” cancer cells. Image quan-
titation revealed that the expression of TOMM20 was reduced 
by >5-fold in NAC-treated HaCaT-Ras cells (data not shown).
Thus, ROS production in HaCaT-Ras cells apparently drives 
mitochondrial biogenesis in epithelial cancer cells, and then 
almost simultaneously “fertilizes” the tumor microenvironment, 
via “bystander” oxidative stress in cancer-associated fibroblasts.
Fibroblasts protect cancer cells against programmed cell 
death
As fibroblasts appeared to protect HaCaT-Ras and HaCaT-p65 
cells against oxidative stress (Fig. 10C), we also examined their 
effects on programmed cell death (apoptosis), which was quanti-
tated by FACS analysis using Annexin-V and PI staining.
Figure 13A shows that fibroblasts did not affect cell death in 
normal HaCaT control cells but significantly rescued HaCaT-
Ras and HaCaT-p65 cells from apoptosis. However, the most 
significant fibroblast-mediated reductions in programmed cell 
death were observed with HaCaT-Ras cells, which showed a 2.4-
fold reduction in apoptosis.
Thus, fibroblasts functionally rescue HaCaT-Ras and 
HaCaT-p65 cells from oxidative stress and programmed cell 
death, likely by reducing oncogene-induced stress.
Fibroblasts confer resistance to autophagy and senescence 
during Ras activation in cancer cells
Previously, we and others have shown that β-galactosidase 
(β-GAL) is a metabolic marker of both autophagy and senes-
cence, as it is a key lysosomal enzyme which accumulates in lyso-
somes and autophagosomes in senescent cells.49-51,54
Since fibroblasts effectively reduced oxidative stress and pro-
tected cancer cells against apoptosis, we also speculated that 
these reductions in oxidative stress may also protect HaCaT-
Ras cells against autophagy and senescence. HaCaT-Ras cells 
should be particularly susceptible to autophagy and senescence, 
as H-Ras (G12V) expression is known to confer significant onco-
genic stress. Thus, we quantitatively measured β-galactosidase 
(β-GAL) activity levels by FACS analysis.
First, we examined β-GAL activity in HaCaT cells (CTRL 
vs. Ras). These results are shown in Figure 13B and C. Note 
that HaCaT-Ras cells cultured alone showed very dramatic 
increases in β-GAL activity, as compared directly with HaCaT 
control cells. However, β-GAL levels were progressively reduced 
Figure 10. Homotypic cultures of epithelial cancer cells show that ras-
transformation increases rOS production and MCt4 expression. HaCat 
epithelial cells (control, H-ras [G12V], or NFkB [p65]) were cultured alone 
and then subjected to either FACS analysis to determine rOS production 
(A), or immunostaining with antibodies directed against MCt4, a marker 
of oxidative stress (B). Note that ras-activation in HaCat cells signifi-
cantly increases rOS production (1.5-fold; P = 0.02) and MCt4 expression 
plasma membrane staining. DAPI (blue nuclear staining) is also shown 
for reference. (C) shows rOS production in HaCat epithelial cells (control, 
H-ras [G12V], or NFkB [p65]) alone or during co-culture with fibroblasts, 
by comparing data presented in Figure  2 and Figure  10A; these data 
are derived from the same experiments. Note that co-culture of normal 
and epithelial cancer cells with fibroblasts reduced rOS-production 
in all cases, indicating that fibroblasts may help induce an antioxidant 
response in adjacent epithelial cells and protect these epithelial cells 
from oxidative stress.
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(by >2-fold) in HaCaT-Ras cells during co-culture with hTERT-
immortalized fibroblasts over a 2–4 day period.
This provides independent support for the idea that cancer 
cells use fibroblasts to rescue themselves from oncogene-induced 
stress and to confer autophagy resistance and suppress senescence 
in cancer cells.
Ras activation in cancer cells significantly alters metabolism 
in normal adjacent epithelial cells, driving oxidative stress and 
glycolysis
To determine if Ras activation in epithelial cancer cells 
also affects metabolism in normal adjacent epithelial cells, 
HaCaT-Ras (RFP[+]) cells were co-cultured with normal 
HaCaT control cells, which are not transformed. Then, these 
epithelial–epithelial co-cultures were subjected to FACS analy-
sis with a series of fluorescent metabolic probes. These small 
reporter molecules allowed us to quantitatively monitor ROS 
production (a measure of oxidative stress) and glucose uptake 
(a measure of glycolysis or glycolytic power) in a compartment-
specific fashion. Thus, we compared ROS production and 
glucose uptake in Ras-transformed epithelial cancer cells and 
adjacent “normal” epithelial cells to determine how epithelial 
oncogene-activation metabolically reprograms adjacent normal 
epithelial cells.
Figure 14 shows the status of these metabolic parameters 
in normal HaCaT control cells co-cultured with HaCaT-Ras 
(RFP[+]) cells. More specifically, we examined ROS production 
and glucose uptake in the population of normal HaCaT control 
cells co-cultured with HaCaT-Ras cells. Significant changes were 
observed in both ROS production and glucose uptake. More spe-
cifically, normal HaCaT control cells that were co-cultured with 
HaCaT-Ras cells showed a significant increase in both ROS pro-
duction (1.7-fold; P = 0.03) and glucose uptake (1.3-fold; P = 6 
× 10−5). Thus, oncogene-transformed epithelial cancer cells can 
metabolically reprogram normal adjacent epithelial cells as well 
as fibroblasts.
In contrast, normal HaCaT control cells did not change ROS 
production or glucose uptake in HaCaT-Ras cells, indicating that 
HaCaT-Ras cells exert a significant dominant effect over normal 
epithelial cells. Thus, unlike fibroblasts, normal epithelial cells 
do not relieve oxidative stress in epithelial cancer cells. This is an 
important distinction, which suggests that fibroblasts also make 
better partners for metabolic symbiosis.
We conclude that epithelial cancer cells can use either adjacent 
fibroblasts, or even adjacent normal epithelial cells, as “partners” 
to engage in a form of “metabolic symbiosis”.
Thus, as previously proposed by Sonveaux, Feron, and 
Dewhirst, a “lactate shuttle” may also exist between two popula-
tions of oxidative and glycolytic epithelial cells.86-88 This occurs 
clinically in head and neck cancers, where the oxidative cancer 
cells with functional mitochondrial are hyper-proliferative and 
are MCT1(+)-positive.83 In contrast, the glycolytic cancer cells 
are mitochondria-deficient, non-proliferative, and are MCT4(+)-
positive.83 As such, this glycolytic cancer cell population may 
actually represent relatively “normal” epithelial cells, which are 
helping to fuel their neighbors via metabolic symbiosis. In fact, 
these glycolytic MCT4(+) epithelial tumor cells appeared to be 
well differentiated in head and neck cancers.83
Discussion
Cancer is a systemic metabolic disease, fueled by oxidative 
stress and inflammation
Here, we provide provocative new evidence that cancer is not a 
cell autonomous disease, but rather it is a systemic disease, of the 
host stromal microenvironment (Fig. 15A). More specifically, we 
show that RAS oncogene-induced ROS production is transmit-
ted from epithelial cancer cells to neighboring normal fibroblasts. 
As a consequence, epithelial ROS production drives the onset of 
the cancer-associated fibroblast phenotype, resulting in an ampli-
fication of ROS production, literally creating a “field of oxidative 
stress”. This has important functional consequences, as ROS pro-
duction in cancer-associated fibroblasts causes a shift toward aer-
obic glycolysis, initiating the “reverse Warburg effect.”33,40,41,84,89 
This fibroblastic shift toward glycolysis was quantitatively fol-
lowed by FACS analysis and NBD–glucose uptake.
Virtually identical results were obtained using epithelial 
cancer cells that were genetically reprogrammed toward a pro-
inflammatory phenotype, via NFkB activation. As such, onco-
gene-induced ROS production and/or inflammation have similar 
negative metabolic effects on the host microenvironment, allow-
ing for effective tumor cell engraftment.
Our results explain how activated oncogenes, inflammation, 
and ROS production “collaborate”, resulting in tumor initiation 
and “fertilization” of the host microenvironment.18,19,35,38 Thus, 
activated oncogenes and chronic inflammation have local and 
systemic metabolic effect(s), which establish metabolic symbio-
sis between epithelial cancer cells and cancer-associated fibro-
blasts.17-19 This metabolic reprogramming results in the paracrine 
establishment of “two-compartment tumor metabolism”90-92.
Figure  11. ras oncogene activation and inflammation both drive the 
upregulation of mitochondrial activity in epithelial cancer cells. HaCat 
epithelial cells (control, H-ras [G12V], or NFkB [p65]) were cultured alone 
and then subjected to FACS analysis to determine mitochondrial activity, 
via Mitotracker staining. Note that HaCat-ras cells (1.5-fold; P = 0.009) 
and HaCat-p65 cells (1.6-fold; P = 0.006) both show a significant increase 
in Mitotracker activity staining.
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Our findings have important practical applications 
for changing the existing paradigm(s) of cancer diag-
nosis, FDG-PET-imaging, and anticancer therapy 
toward more holistic and non-toxic approaches.18,25 
They also directly implicate the use of antioxidants 
and anti-inflammatory therapies in cancer prevention 
and personalized medicine.42-45,93
Hence, cancer may be viewed as a host-based dis-
ease of chronic oxidative stress and inflammation that 
starts locally as a point source in the cancer cell, which 
is then amplified and spreads systemically in the host, 
ultimately driving whole-body catabolism and “meta-
bolic catastrophe” or “metabolic collapse”, especially 
during metastasis.
Diverse oncogenic stimuli converge on a com-
mon druggable target: MCT4 in the tumor 
microenvironment
Cancer cells use oncogene-driven oxidative stress 
as a “weapon” to induce a specific metabolic response 
to injury in the tumor microenvironment, allowing 
them to establish metabolic symbiosis and successful 
cancer cell engraftment within the host organism. In 
many ways, our current results are consistent with the 
“seed and soil” hypothesis, which was originally pro-
posed in 1889, by Dr Stephen Paget in England, more 
than 100 y ago.94-97
We conclude that oncogenes can also act at a dis-
tance, via ROS production and inflammation, to induce meta-
bolic symbiosis between cancer cells and the tumor stroma. 
Diverse oncogenes (Ras and NFkB) may act via a common 
convergent mechanism (oxidative stress), to upregulate MCT4 
in the tumor stroma (Fig. 15B). In addition, we have previously 
shown that several other pro-oncogenic stimuli, such as loss of 
BRCA1,20,21 TGF-β secretion,98 and ethanol treatment,99 as well as 
ROS and hydrogen peroxide (H
2
O
2
) production,56 all converge on 
Cav-1 downregulation and MCT4 upregulation in the tumor stro-
mal compartment. As such, changes in the expression of stromal 
Cav-1/MCT4 can be used to monitor the transition to malignancy 
during tumor initiation and progression. Taken together, these 
data make stromal MCT4 an attractive new druggable target for 
novel therapeutic interventions, as MCT4 controls the “food” sup-
ply for cancer cells.56,83,84
In summary, oncogenic stress stimulates a common metabolic 
response to “injury” in the tumor microenvironment. This idea 
is consistent with the hypothesis that cancer behaves as a wound 
that does not heal (Fig. 16).
Cancer cells behave as “metabolic parasites”: Can we treat 
cancer like an infectious disease with “metabolic” antibiotics?
The parallels with infectious disease are now clear. Cancer cells 
behave as predatory “metabolic parasites”, just like foreign micro-
organisms (bacteria, fungi, and viruses).31,36,40,44 Thus, we should 
consider treating cancer like an infectious disease, with new 
classes of “metabolic” antibiotics that can starve cancer cells to 
death.
Some of these “metabolic” antibiotics may already be avail-
able. For example, tigecycline, a member of the tetracycline 
family of antibiotics, selectively kills cancer cells (but not normal 
cells), by preventing mitochondrial biogenesis in cancer cells.100 
Furthermore, doxycyline, another tetracycline family member, 
inhibits breast cancer metastasis by >70% in pre-clinical animal 
models,101 likely by targeting mitochondrial protein synthesis in 
cancer cells.102
In accordance with these findings, we have previously shown 
that 15 markers of mitochondrial biogenesis are increased in 
human breast cancer cells in vivo (e.g., TOMM20, MCT1, MRP 
[mitochondrial ribosomal proteins]),93 and that the overexpres-
sion of genes that functionally drive mitochondrial biogenesis 
(GOLPH3, PGC1a/b, MitoNEET, or POLRMT)91,92 in breast 
cancer cells is indeed sufficient to increase tumor growth rates in 
xenografted mice.
Interestingly, we also show here that NAC halts mitochondrial 
biogenesis in Ras-transformed epithelial cancer cells, most likely 
by eliminating oxidative stress. Thus, NAC targets both epithe-
lial cancer cells and the tumor microenvironment, “hitting” mul-
tiple genetic and spatial targets at the same time.
Inflammation is a critical mediator of the transition to 
malignancy: Implications for chemoprevention with anti-
inflammatory drugs
It has long been suggested that chronic inflammation (due 
to injury or infections), may be a critical trigger for tumor ini-
tiation.103,104 In accordance with this notion, the most com-
mon global causes of cancer are due to infections in the cervix 
(HPV), liver (HBV), lung (TB), nasopharyngeal tissues (EBV), 
and stomach (H. pylori). In addition, other chronic inflamma-
tory conditions, such as ulcerative colitis, Crohn disease, and 
Figure  12. Antioxidant treatment selectively inhibits mitochondrial biogenesis in 
ras-transformed epithelial cancer cells. HaCat epithelial cells (control, H-ras [G12V], 
or NFkB [p65]) were cultured alone (in the absence or presence of NAC [10 mM]) and 
then subjected to immunostaining with tOMM20, a marker of mitochondrial mass. 
Note that HaCat-ras cells show the most significant increase in mitochondrial mass, 
and that this is strictly dependent on oxidative stress. DAPI (blue nuclear staining) is 
also shown for reference.
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scleroderma, all lead to an increased risk of developing cancer. 
Moreover, in the GI tract, ROS-producing bacteria have been 
implicated in the initiation of colon cancer. Finally, H. pylori 
also increases ROS (hydrogen peroxide) and 
RNS (nitric oxide) in the stomach.
Notably, in DCIS patients, loss of stromal 
Cav-1 is directly associated with inflamma-
tion in the tumor stroma.71 More specifically, 
in this patient cohort, either loss of stromal 
Cav-1 or inflammation were both individu-
ally sufficient to predict DCIS recurrence 
and progression to invasive breast cancer.71 
Importantly, loss of stromal Cav-1 was a better 
predictor (as compared with inflammation) of 
DCIS recurrence and/or progression, indicat-
ing that glycolytic stromal metabolism is the 
most critical event for tumor progression.71
Similarly, we have shown here that onco-
genes and inflammation induce a loss of 
Cav-1, as well as increased oxidative stress, 
and glycolysis in the host microenvironment. 
This leads to metabolic symbiosis between 
oxidative cancer cells and glycolytic stromal 
fibroblasts. Thus, inflammation is a critical 
mediator of tumor initiation and progression, 
suggesting that we should consider new anti-
inflammatory strategies for chemoprevention, 
and as anticancer therapies.
Understanding the desmoplastic reac-
tion, during the transition to malignancy: 
Implications for cancer therapy
The “desmoplastic reaction” refers to the 
growth of connective 
tissue fibroblasts or stroma in and around an area, usually 
in response to an injury or the presence of a focus of cancer 
Figure 13. Fibroblasts protect cancer cells against 
apoptosis, autophagy, and sensecence: quan-
titation via FACS. (A) Apoptosis. Cell death was 
quantified by flow cytometry using propidium 
iodide and Annexin-V-APC. After a total of 4 days 
in culture, the cells were collected by centrifu-
gation. then, the annexin V-APC conjugate and 
propidium iodide was added. Cells were then 
analyzed by flow cytometry. Note that fibroblasts 
(GFP[+]) did not affect cell death in HaCat con-
trol cells, but significantly rescued HaCat-ras and 
HaCat-p65 cells from apoptosis. However, the most 
significant fibroblast-mediated reductions in cell 
death were observed with HaCat-ras cells, which 
showed a 2.4-fold reduction in apoptosis. (B and 
C) Autophagy and senescence. Cells were treated 
using the Fluoreporter lacZ Flow Cytometry Kit 
(Molecular probes). Assay results were evaluated by 
flow-cytometry analysis. Note that HaCat-ras cells 
cultured alone showed very dramatic increases in 
β-GAL activity, as compared directly with HaCat 
control cells. However, β-GAL levels were pro-
gressively reduced (by >2-fold) in HaCat-ras cells 
during co-culture with htert-immortalized fibro-
blasts, over a 2–4 d period. thus, fibroblasts induce 
autophagy-resistance and reverse senescence in 
HaCat-ras cancer cells. (B) Day 2 co-culture; (C) day 
4 co-culture.
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cells.15,105-107 Thus, the desmoplastic reaction is part of the normal 
wound response and is consistent with the notion that a tumor is 
a wound that does not heal.105
In tumors, the desmoplastic reaction is most often associ-
ated with myo-fibroblastic differentiation and the increased 
secretion of extracellular matrix proteins, such as collagen I and 
tenascin C, among others.108 This can also lead to scar forma-
tion. Interestingly, tumors with a “central scar” or “fibrotic focus” 
are associated with a worse clinical outcome, such as recurrence, 
metastasis, and poor overall survival.109-114
Given our current findings, a new function for the desmoplas-
tic reaction, which is a common feature of many different types 
of malignancies, may be to help cancer cells overcome oncogenic 
stress. More specifically, we show here that glycolytic stromal 
fibroblasts reduce oxidative stress in cancer cells, which effec-
tively protects these cancer cells against apoptosis, autophagy, 
and even senescence.
Indeed, over the years, it has proved quite difficult to generate 
new cancer cells lines, in addition to the NCI-60 panel of tumor 
cells. One possible explanation is that primary cancer cells suffer 
from oncogene-induced senescence, and that this becomes most 
apparent when we isolate cancer cells away from stromal cells in 
an attempt to have pure cultures of cancer cells. Thus, the best 
way to kill primary cancer cells may be to separate them from 
stromal fibroblasts.
As such, new therapies should be developed to target the tumor 
stroma. Once stromal cells are effectively killed, an expected con-
sequence would be the onset of oncogene-induced senescence in 
the primary cancer cells, resulting in tumor regression.
Materials and Methods
Materials
Antibodies were as follows: MCT4 and MCT1 (generous 
gifts of Dr Nancy Philp, which are isoform-specific rabbit poly-
clonal antibody against 18-mer synthetic oligo-peptides cor-
responding to the C-terminal amino acids of human MCT4 or 
MCT1115); TOMM20 (sc-17764, Santa Cruz Biotechnologies). 
Secondary antibodies for immunofluorescence were Alexa 
Orange-Red 546 nm and Alexa far red 633 nm (Invitrogen). 
Other reagents were as follows: N-acetyl cysteine (NAC) 
was from Sigma, 2-(N-[7-nitrobenz-2-oxa-1,3-diazol-4-yl]
amino)-2-deoxy-D-glucose (2-NBDG), 4,6-diamidino-
2-phenylindole (DAPI) were from Invitrogen. The CellROX 
assay for measuring reactive oxygen species was from 
Invitrogen.
Figure 14. HaCat epithelial-cancer cell co-cultures: Oncogene-transformed cancer cells can metabolically reprogram normal adjacent epithelial cells. 
(A) rOS-production. (B) Glucose uptake. HaCat-ras (rFP[+]) epithelial cancer cells were co-cultured for 4 days with normal HaCat control cells. then, 
rOS production (a measure of oxidative stress) and glucose uptake (a measure of glycolytic activity) in both cell types were quantitatively determined 
by FACS sorting. Note that normal HaCat control cells co-cultured with HaCat-ras cells show a significant increase in both rOS production (1.7-fold; 
P = 0.03) and glucose uptake (1.3-fold; P = 6 × 10−5). However, normal HaCat control cells did not change rOS production or glucose uptake in HaCat-ras 
cells, indicating that HaCat-ras cells exert a significant dominant effect over normal epithelial cells. thus, oncogene-transformed epithelial cancer cells 
can metabolically reprogram adjacent normal epithelial cells, to establish “metabolic symbiosis”.
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Cell cultures
The HaCaT cancer cell lines were provided by Dr Ulrich 
Rodeck and experiments were performed in the recommended 
complete growth medium (DMEM with 10% FBS and Penicillin 
100 units/mL-Streptomycin 100 µg/mL). Human skin fibro-
blasts (BJ-1) immortalized with the telomerase reverse transcrip-
tase catalytic domain (hTERT) were originally purchased from 
Clontech, Inc, and clones were generated with either GFP or RFP 
Figure 15. Diverse oncogenic stimuli metabolically rewire the microen-
vironment, via a common mechanism. (A) Oxidative stress and inflamma-
tion reprogram the microenvironment. Here, we show that activation of 
ras or the innate immune response in epithelial cancer cells are both suf-
ficient to actively induce metabolic reprogramming of the tumor micro-
environment. rOS production and/or cytokine release drives oxidative 
stress in adjacent cancer-associated fibroblasts. Oxidative stress in myo-
fibroblasts then mediates the induction of stromal aerobic glycolysis, i.e., 
“metabolic symbiosis” or the “reverse Warburg effect”. thus, diverse epi-
thelial oncogenes (H-ras [G12V] and NFkB [p65]) induce oxidative stress 
in the tumor stroma. MCt1 and MCt4 are markers of metabolic symbio-
sis. (B) Oncogenic stimuli converge on stromal MCt4. HaCat cells which 
harbor activated oncogenes gain the ability to glycolytically reprogram 
the tumor microenvironment, via the induction of oxidative stress in 
cancer-associated fibroblasts. thus, diverse oncogenes (ras and NFkB) 
act via a common mechanism (oxidative stress), to upregulate MCt4 in 
the tumor stroma. As MCt4 controls the “energy” supply for cancer cells, 
this makes MCt4 an attractive target, for new therapeutic interventions 
aimed at “starving” tumor cells. Similarly, other pro-oncogenic stimuli, 
such as loss of BrCA1, tGF-β secretion, and ethanol, as well as rOS and 
hydrogen peroxide production, all converge on MCt4 upregulation in 
the tumor stromal compartment. In addition, all these pro-oncogenic 
stimuli (rAS, NFkB, BrCA1 loss, tGF-β, rOS/H2O2, and ethanol) also drive 
a loss of stromal Cav-1 expression in cancer associated fibroblasts. thus, 
Cav-1 and MCt4 are stromal biosensors of the transition to malignancy.
overexpression. BJ-1-GFP or BJ-1-RFP fibroblasts were cultured 
in HaCaT complete growth media. After 24 h, the media was 
changed to DMEM with 10% nuserum and penicillin 100 units/
mL-streptomycin 100 µg/mL.
Co-cultures of HaCaT cells and fibroblasts
BJ-1 fibroblasts overexpressing GFP or RFP and one of 
the HaCaT cell lines (HaCaT-CTRL, HaCaT-Ras(G12V), 
HaCaT-p65) were plated on glass coverslips in 12-well plates in 1 
ml of complete media. Epithelial cells were plated within 2 h of 
fibroblast plating. The total number of cells per well was 1 × 105. 
Experiments were performed at a 5:1 fibroblast-to-epithelial cell 
ratio. As controls, homotypic mono-cultures of fibroblasts and 
epithelial cells were seeded using the same number of cells as the 
total corresponding co-cultures. Cells were maintained at 37 °C 
in a humidified atmosphere containing 5% CO
2
.
Co-cultures of HaCaT-control cells and HaCaT-Ras cells
HaCaT-Ras cells overexpressing RFP and HaCaT-Control cell 
lines were plated onto glass coverslips in 12-well plates in 1 ml 
of complete media. Both cell lines were plated within 2 h of the 
one being plated. The total number of cells per well was 1 × 105. 
Experiments were performed at a 5:1 HaCaT-Control -to-HaCaT-
Ras cell ratio. As controls, homotypic mono-cultures of HaCaT-
Control and HaCaT-Ras cells were seeded using the same number 
of cells as the total corresponding co-cultures. Cells were main-
tained at 37 °C in a humidified atmosphere containing 5% CO
2
.
Flow cytometric analysis
HaCaT cells were plated in co-culture with BJ-1 fibroblasts 
(which were either GFP [+] or RFP[+]) or plated in mono-cul-
ture. Cells were grown for a total culture duration of 4 d. Then, 
to isolate the GFP(+) or RFP(+) BJ-1 cell population, co-cultured 
cells were sorted using a 488 nm and a 543 nm laser. As a critical 
control, mono-cultures of Hacat cells, which are GFP(−), and 
BJ-1 fibroblast cells, which are GFP (+) or RFP (+), were sorted 
in parallel.
Measurement of reactive oxygen species
CellROX (cat #C10422, Invitrogen) is a cell-permeable dye 
used to measure intracellular ROS. CellROX is non-fluorescent 
in a reduced state. When oxidized by reactive oxygen species 
witihin cells it has high fluorescence, with absorption/emission 
maxima of ~644–665 nm. The fluorescence method was used 
according to the manufacturer’s instructions. Briefly, BJ-1 fibro-
blasts which were RFP(+) were cultured homotypically or in co-
culture with HaCaT cells. Cells were then incubated with 5 μM 
CellROX in DMEM with 10% FBS for 30 min at 37 °C. Cells 
were then washed in PBS ×3, harvested, and re-suspended in 500 
μL of PBS. Cells were analyzed by flow cytometry using an RFP 
signal detector to distinguish fibroblasts from HaCaT cells (fibro-
blasts are the RFP[+] population) and an APC signal detector to 
measure levels of intracellular reactive oxygen species.
Measurement of glucose uptake
Glucose uptake was performed using 2-NBDG. HaCaT 
cells in homo-typic culture or co-cultured with BJ-1 fibroblasts 
(RFP[+]) were cultured for 4 d. Then, the cells were incubated 
with 2-NBDG solution (diluted in phenol red free DMEM with 
10% FBS to a final concentration of 250 μM) for 30 min at 37 
°C. All subsequent steps were performed in the dark. Cells were 
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then washed in PBS, harvested, and re-suspended in 500 μL of 
PBS. Cells were then analyzed by flow cytometry using a GFP 
signal detector with excitation wavelength of 488 nm and emis-
sion of 530 nm (to detect 2-NBDG), and an RFP signal detector 
with excitation wavelength of 496 nm and emission of 615 (to 
detect RFP-positive BJ-1 cells). Thus, HaCaT cells in co-culture 
were the RFP-negative population.
Mitochondrial activity
To measure mitochondrial activity, cells were stained with 
MitoTracker Orange (CMTMRos cat #M7510, Invitrogen), 
whose accumulation in mitochondria is dependent upon mem-
brane potential. Briefly, HaCaT cells were cultured alone for 3 
days in DMEM with 10% NuSerum. Cells were then incubated 
with pre-warmed MitoTracker staining solution (diluted in serum 
free DMEM to a final concentration of 10 nM) for 10 min at 37 
°C. All subsequent steps were performed in the dark. Cells were 
washed in PBS, harvested, and re-suspended in 500 μL of PBS. 
Cells were then analyzed by flow cytometry using a GFP signal 
detector with excitation wavelength of 488 nm and emission of 
530 nm (to detect GFP-positive fibroblasts), and a PE Texas Red 
signal detector with excitation wavelength of 496 nm and emis-
sion of 615 (to detect MitoTracker). Data analysis was performed 
using FlowJo 8.8 software.
Immunocytochemistry
Cells were fixed after 4 days of culture. Then, the ICC proto-
col was performed as previously described, with minor modifica-
tions.56 Briefly, cells were fixed for 30 min at room temperature 
in 2% para-formaldehyde diluted in PBS, after which they were 
permeabilized with cold methanol at −20 °C for 5 min. The cells 
were rinsed with PBS with 0.1 mM calcium chloride and 1 mM 
magnesium chloride (PBS/CM). Then, cells were incubated with 
NH4Cl in PBS to quench free aldehyde groups. Rinsing with 
PBS/CM was followed by blocking with immunofluorescence 
(IF) buffer (PBS, 1% BSA, 0.1% Tween 20) for 1 h at room tem-
perature. Primary anti-MCT4 and TOMM20 antibodies were 
incubated in IF buffer for 1 h at room temperature. 
After washing with IF buffer (3×, 10 min each), 
cells were incubated for 30 min at room tempera-
ture with fluorochrome-conjugated anti-rabbit and 
anti-mouse secondary antibodies diluted in IF buf-
fer. Finally, slides were washed at room temperature 
with IF buffer (3×, 10 min each), rinsed with PBS/
CM and counter-stained with DAPI (1 μg/ml) in 
PBS and mounted with Prolong Gold anti-fade 
reagent.
Confocal microscopy
Images were collected with a Zeiss LSM510 meta 
confocal system using a 405 nm diode excitation 
laser with a band pass filter of 420–480 nm, a 488 
nm Argon excitation laser with a band pass filter of 
505–550 nm, a 543 nm HeNe1 excitation laser with 
a 561–604 nm filter and a 633 nM HeNe2 excita-
tion laser with a 657–754 nm filter. Images were 
acquired with a 40× objective. Immunofluorescence 
staining image quantitation was performed using 
ImageJ 1.46 (National Institutes of Health,). 
Briefly, the channel was split into 8-bit single color images. 
Polygon selection was used to delineate the cells so as to measure 
cell fluorescence intensity and area. Quantification was expressed 
as intensity per unit area intensity/area(pixel2). Different condi-
tions were compared by Student t test.
Apoptosis measurement
Cell death was quantified by flow cytometry using propidium 
iodide and Annexin-V-APC, as previously described, with minor 
modifications.23 Briefly, HaCaT cells and BJ-1 cells were plated 
in 12-well plates, with the BJ-1 cells being GFP(+). The day after, 
media was changed to DMEM with 10% NuSerum. After a total 
of 4 d in culture, cells were collected by centrifugation and re-
suspended in 500 μL of Annexin-V binding buffer. Then, the 
annexin V-APC conjugate (BD Biosciences 550474) (4 μL) and 
propidium iodide (1 μL) was added and incubated in the dark at 
room temperature for 5 min. Cells were then analyzed by flow 
cytometry using a GFP signal detector (to detect BJ-1-GFP cells), 
a PE Texas Red signal detector and an APC signal detector.
Beta-galactosidase assay
Assays were performed as previously described.50 Briefly, 
240 000 cells were seeded per well in 6-well plates in DMEM 
with 10% FBS and 1% P/S. The next day, the media was 
changed to DMEM with 10% Nu serum. Cells were then incu-
bated at 37 °C with 5% CO
2
, under normal conditions. Then, 
the cells were trypsinized, centrifuged, and counted to obtain 
106 cells. Afterwards, cells were treated according the manufac-
turer’s instructions, using the FluoReporter lacZ Flow Cytometry 
Kit (Molecular probes, #F-1930). Assay results were evaluated by 
flow-cytometry analysis.
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Figure 16. Understanding why cancer behaves as a wound that does not heal. Oncogenic 
stress stimulates a common metabolic response to “injury” in the tumor microenviron-
ment. Four steps or events are outlined, leading to “metabolic symbiosis”. this idea is 
consistent with the hypothesis that cancer behaves as a wound that does not heal.
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